Baird initiated coverage of Arcellx with an Outperform rating and $39 price target. The company’s lead asset is CART-ddBCMA, an autologous CART for the treatment of multiple myeloma, the analyst tells investors in a research note. Clinical data from the Phase 1 study leads the firm to believe this treatment possesses "best-in-class potential." Further, it is encouraged by the recent co-development/co-promotion deal with Kite, a leader in the CART space.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ACLX:
- Arcellx price target raised to $39 from $35 at SVB Securities
- Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
- Arcellx reports Q4 net loss $39.0M vs. $20.7M last year
- Arcellx initiated with a Buy at Stifel
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
